+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Transdermal nicotine for smoking cessation in postmenopausal women

Transdermal nicotine for smoking cessation in postmenopausal women

Addictive Behaviors 32(2): 296-309

This study examined the efficacy of transdermal nicotine in postmenopausal smokers, and whether a history of depression or hormone replacement therapy (HRT) moderated smoking cessation outcomes. Postmenopausal smokers (N=152) received intensive smoking cessation counseling and were randomly assigned to use either a 2 1 mg nicotine patch for 3 months, with a 1-month taper, or a placebo patch. The primary outcome was biochemically validated 7-day point prevalence smoking abstinence during treatment (i.e., 1, 2, 6, and 12 weeks after the quit date) and I year after study medication was discontinued. Subjects who received transdermal nicotine were significantly more likely than placebo-treated subjects to remain abstinent from smoking during treatment, but not at the 1-year follow-up. The majority of subjects (> 50%) in both groups accurately identified their treatment assignment. History of depression was associated with a decreased likelihood to abstain from smoking throughout the study. HRT did not moderate smoking outcomes. These data indicate that transdermal nicotine may provide short-term benefits for smoking cessation in postmenopausal women. However, efforts are needed to improve long-term abstinence rates and smoking outcomes among women with a history of depression.

(PDF emailed within 0-6 h: $19.90)

Accession: 013028333

Download citation: RISBibTeXText

PMID: 16765526

DOI: 10.1016/j.addbeh.2006.04.004

Related references

Effect of transdermal nicotine on weight gain with smoking cessation in postmenopausal women. Journal of Investigative Medicine 50(2): 165A, March, 2002

Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials. Transdermal Nicotine Study Group. JAMA 266(22): 3133-3138, 1991

Cholesterol changes in smoking cessation using the transdermal nicotine system. Transdermal Nicotine Study Group. Preventive Medicine 23(2): 190-196, 1994

Effect of nicotine patch on energy intake and weight gain in postmenopausal women during smoking cessation. Eating Behaviors 14(4): 420-423, 2014

Comparison of fixed-dose transdermal nicotine, tapered-dose transdermal nicotine and buspirone in smoking cessation. Journal of Allergy & Clinical Immunology 91(1 PART 2): 171, 1993

Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clinical Pharmacology and Therapeutics 79(6): 600-608, 2006

Efficacy of transdermal nicotine patches for nicotine replacement and smoking cessation. Nurse Practitioner 17(7): 46-48, 1992

Efficacy of transdermal nicotine administrations as an adjunct for smoking cessation in heavily nicotine addicted smokers. American Review of Respiratory Disease 139(4 PART 2): A337, 1989

Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacology, Biochemistry, and Behavior 92(1): 6-11, 2008

Transdermal nicotine after smoking cessation. American Journal of Psychiatry 151(4): 624-625, 1994

The use of transdermal nicotine in smoking cessation. Lung 168 Suppl: 445-453, 1990

Transdermal nicotine for smoking cessation. American Review of Respiratory Disease 145(4 PART 2): A685, 1992

Transdermal nicotine patch for smoking cessation. New England Journal of Medicine 326(5): 344; Author Reply 345-344; Author Reply 345, 1992

Transdermal nicotine replacement and smoking cessation. American Family Physician 45(6): 2595-2602, 1992

Smoking cessation using the transdermal nicotine system. Lijecnicki Vjesnik 125(1-2): 8-12, 2003